Table 2.

Clinical and laboratorial characteristics before and after follow-up.

	Group 1 (n = 20)		Group 2 (n = 62)		Group 3 (n = 33)		p-value
	Initial (Mean ± SD)	Final (Mean ± SD)	Initial (Mean ± SD)	Final (Mean ± SD)	Initial (Mean ± SD)	Final (Mean ± SD)
Age (years)	11.4 ± 2.2	12.5 ± 2.2	9 ± 2.8	10 ± 2.8	10.7 ± 2.1	11.8 ± 2.1	<0.05*
BA (years)	8.5 ± 2.6	10.1 ± 2.6	6.7 ± 3.3	8.5 ± 3.4	9.4 ± 2.6	10.8 ± 2.5	<0.05*
BMI (kg/m2)	15.9 ± 3.1	15.1 ± 3.7	17.3 ± 3.5	17.5 ± 3.3	17.6 ± 3.3	18.5 ± 3.6	NS
BMI-SDS	−1.2 ± 1.7	−1.3 ± 1	0.1 ± 1.7	0.1 ± 1.3	−0.01 ± 1.5	−0.02 ± 1.6	NS
Height (cm)	126 ± 10	131.7 ± 10.6	121.1 ± 17.2	131.2 ± 17.3	127.8 ± 14	135 ± 15.1	<0.05*
H-SDS	−3 ± 0.6	−3 ± 0.7	−1.9 ± 1.4	−1.1 ± 1.2	−2.1 ± 1.5	−2.1 ± 1.5	<0.05 †
PH (cm)	162.3 ± 11	162.1 ± 10	166.5 ± 11.8	172.4 ± 11.9	160.8 ± 13.1	163.2 ± 15.5	<0.05
PH-SDS	−1.8 ± 1.4	−1.7 ± 1.3	−0.9 ± 1.1	−0.2 ± 1.2	−1.7 ± 1.4	−1.4 ± 1.8	<0.05
IGFBP3 (μg/mL)	–	–	3.8 ± 1.3	5.2 ± 0.9	4.1 ± 1.4	5.4 ± 0.7	<0.05
IGF-1 (μg/L)	215.2 ± 100	–	198.6 ± 179	342.1 ± 167.7	194 ± 113	413 ± 160.7	<0.05
IGF-1 SDS	−0.4 ± 1.5	–	−0.4 ± 2.1	1.5 ± 1.5	−0.7 ± 1.6	0.9 ± 1.4	<0.05
RhGH dose (U/kg/week)	–	–	0.9 ± 0.2	0.9 ± 0.1	0.9 ± 0.1	0.9 ± 0.2	NS

^*p < 0.05 (initial vs. final within all groups).

p < 0.05 (initial vs. final within group 2).

p < 0.05 (initial vs. final within group 3).

^†p < 0.05 (final vs. final between all three groups).

Group 1: children diagnosed with FSS or CDGP; Group 2: children who gained 0.3 SD in height after 1 year of rhGH treatment; Group 2: children who gained <0.3 SD in height after 1 year of rhGH treatment. BA, Bone age; BMI, Body Mass Index; BMI-SDS, Body Mass Index standard deviations; NS, not significant; H-SDS, Height standard deviations; PH, Predicted Height; PH-SDS, Predicted Height standard deviations; IGF-1, Insulin-like Growth Factor 1; IGF-1 SDS, Insulin-like Growth Factor 1 standard deviations; FSS, Familial Short Stature; CDGP, Constitutional delay of growth and puberty; rhGH, Recombinant Human Growth Hormone.